INKT
MiNK Therapeutics, Inc.
Price Chart
Latest Quote
$12.05
-0.06 (-0.50%)
Current Price
| Previous Close | $12.11 |
| Open | $11.97 |
| Day High | $12.07 |
| Day Low | $11.97 |
| Volume | 2,549 |
Stock Information
| Shares Outstanding | 4.98M |
| Cash Equivalents | $9.53M |
| Net Income | $-12.47M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $60.03M |
| EPS (TTM) | $-2.80 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $50.81M |
| Income | $-12.47M |
| Book/sh | $-2.55 |
| Cash/sh | $1.91 |
| Employees | 15 |
Financial Ratios
| Quick Ratio | 1.31 |
| Current Ratio | 1.38 |
Returns & Margins
| ROA | -110.89% |
Ownership
| Insider Ownership | 60.63% |
| Institutional Ownership | 2.53% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.22 |
| P/B | -4.72 |
Analyst Data
| Recommendation | none |
| Target Price | $39.00 |
Technical Indicators
| SMA20 | $12.16 |
| SMA50 | $11.69 |
| SMA200 | $12.14 |
| RSI | 42.86 |
| ATR | 0.7400 |
| Shares Float | 1.95M |
| Short Float | 4.78% |
| Short Ratio | 2.97 |
| Volatility | 0.47 |
| Rel Volume | 0.06 |
Performance History
| Week | -1.31% |
| Month | +15.42% |
| Quarter | +32.05% |
| 6 Months | +3.34% |
| YTD | +8.36% |
| Year | +62.40% |
| 3 Years | -55.70% |
| 10 Years | -89.96% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $12.05 | 2,549 |
| 2026-06-24 | $12.11 | 7,000 |
| 2026-06-23 | $12.33 | 22,800 |
| 2026-06-22 | $12.25 | 19,800 |
| 2026-06-18 | $12.14 | 16,500 |
| 2026-06-17 | $12.21 | 22,800 |
| 2026-06-16 | $11.81 | 23,100 |
| 2026-06-15 | $12.53 | 27,500 |
| 2026-06-12 | $12.02 | 28,200 |
| 2026-06-11 | $12.34 | 108,800 |
| 2026-06-10 | $12.19 | 27,900 |
| 2026-06-09 | $11.82 | 29,000 |
| 2026-06-08 | $11.34 | 21,500 |
| 2026-06-05 | $11.87 | 51,500 |
| 2026-06-04 | $12.75 | 36,400 |
| 2026-06-03 | $12.76 | 37,700 |
| 2026-06-02 | $11.96 | 38,100 |
| 2026-06-01 | $12.38 | 64,800 |
| 2026-05-29 | $12.20 | 64,000 |
| 2026-05-28 | $12.20 | 214,600 |
| 2026-05-27 | $10.18 | 13,100 |
| 2026-05-26 | $10.44 | 16,500 |
About MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS). It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including in graft-versus-host disease prevention. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York.
đ° Latest News
We're Not Very Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Rate
Simply Wall St. âĸ 2026-05-18T10:24:50Z
MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Strategic Advances and Financial ...
GuruFocus.com âĸ 2026-05-15T23:01:44ZMiNK (INKT) Q4 2025 Earnings Call Transcript
Motley Fool âĸ 2026-05-15T15:41:01Z
MiNK Therapeutics Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-15T14:12:26Z
MiNK Therapeutics Inc (INKT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial ...
GuruFocus.com âĸ 2026-03-31T19:01:53ZMiNK Therapeutics, Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-03-31T16:43:04Z
MiNK Therapeutics Q4 Earnings Call Highlights
MarketBeat âĸ 2026-03-31T13:26:19Z
Wall Street Stabilizes After Oil-Driven Volatility as US Equity Futures Waver Pre-Bell
MT Newswires âĸ 2026-03-10T13:11:05ZAgenus (AGEN) Q2 2025 Earnings Call Transcript
Motley Fool âĸ 2026-01-27T16:43:55Z
MiNK Therapeutics Inc (INKT) Q3 2025 Earnings Call Highlights: Promising Clinical Results and ...
GuruFocus.com âĸ 2025-11-14T21:01:46Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $12,487,304 | $10,650,239 | $22,921,105 | $30,949,278 |
| Other Income Expense | $-187,202 | $-307,131 | $-10 | $2,704,743 |
| Other Non Operating Income Expenses | $-32,370 | $330,915 | $-10 | $2,704,743 |
| Net Non Operating Interest Income Expense | $180,246 | $172,568 | $463,256 | $253,323 |
| Operating Expense | $12,487,304 | $10,650,239 | $22,921,105 | $30,949,278 |
| General And Administrative Expense | $6,729,817 | $4,314,164 | $7,431,108 | $7,834,155 |
| Total Other Finance Cost | - | - | - | $-253,323 |
| Interest Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Other Operating Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-12,494,260 | $-10,784,802 | $-22,457,859 | $-27,991,212 |
| Net Interest Income | $180,246 | $172,568 | $463,256 | $253,323 |
| Interest Income | $180,246 | $172,568 | $463,256 | $253,323 |
| Normalized Income | $-12,339,428 | $-10,146,756 | $-22,457,859 | $-27,991,212 |
| Net Income From Continuing And Discontinued Operation | $-12,494,260 | $-10,784,802 | $-22,457,859 | $-27,991,212 |
| Total Operating Income As Reported | $-12,642,136 | $-11,288,285 | $-22,921,105 | $-30,949,278 |
| Net Income Common Stockholders | $-12,494,260 | $-10,784,802 | $-22,457,859 | $-27,991,212 |
| Net Income | $-12,494,260 | $-10,784,802 | $-22,457,859 | $-27,991,212 |
| Net Income Including Noncontrolling Interests | $-12,494,260 | $-10,784,802 | $-22,457,859 | $-27,991,212 |
| Net Income Continuous Operations | $-12,494,260 | $-10,784,802 | $-22,457,859 | $-27,991,212 |
| Pretax Income | $-12,494,260 | $-10,784,802 | $-22,457,859 | $-27,991,212 |
| Interest Income Non Operating | $180,246 | $172,568 | $463,256 | $253,323 |
| Operating Income | $-12,487,304 | $-10,650,239 | $-22,921,105 | $-30,949,278 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-2.93 | $-2.86 | $-6.54 | $-8.30 |
| Basic EPS | $-2.93 | $-2.86 | $-6.54 | $-8.30 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-12,150,727 | $-9,796,756 | $-22,716,488 | $-30,827,529 |
| Total Unusual Items | $-154,832 | $-638,046 | - | $0 |
| Total Unusual Items Excluding Goodwill | $-154,832 | $-638,046 | - | $0 |
| Reconciled Depreciation | $181,745 | $215,437 | $204,617 | $121,749 |
| EBITDA (Bullshit earnings) | $-12,305,559 | $-10,434,802 | $-22,716,488 | $-30,827,529 |
| EBIT | $-12,487,304 | $-10,650,239 | $-22,921,105 | $-30,949,278 |
| Diluted Average Shares | $4,270,470 | $3,773,326 | $3,435,994 | $3,367,292 |
| Basic Average Shares | $4,270,470 | $3,773,326 | $3,435,994 | $3,367,292 |
| Diluted NI Availto Com Stockholders | $-12,494,260 | $-10,784,802 | $-22,457,859 | $-27,991,212 |
| Gain On Sale Of Security | $-154,832 | $-638,046 | - | - |
| Research And Development | $5,757,487 | $6,336,075 | $15,489,997 | $23,115,123 |
| Selling General And Administration | $6,729,817 | $4,314,164 | $7,431,108 | $7,834,155 |
| Other Gand A | $6,729,817 | $4,314,164 | $7,431,108 | $7,834,155 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-14,227,659 | $-19,585,882 | $-18,055,449 | $-401,303 |
| Total Assets | $14,238,842 | $5,720,813 | $4,552,281 | $21,471,602 |
| Total Non Current Assets | $390,869 | $732,929 | $953,977 | $1,066,910 |
| Current Assets | $13,847,973 | $4,987,884 | $3,598,304 | $20,404,692 |
| Other Current Assets | $211,202 | $164,244 | $177,964 | $470,300 |
| Prepaid Assets | $276,431 | $246,600 | $53,111 | $298,667 |
| Cash Cash Equivalents And Short Term Investments | $13,360,340 | $4,577,040 | $3,367,229 | $19,635,725 |
| Cash And Cash Equivalents | $13,360,340 | $4,577,040 | $3,367,229 | $19,635,725 |
| Current Deferred Assets | - | - | - | - |
| Receivables | - | - | - | - |
| Taxes Receivable | - | - | - | - |
| Cash Financial | - | - | - | - |
| Debt | ||||
| Total Debt | $5,179,444 | $4,924,612 | - | - |
| Current Debt And Capital Lease Obligation | $5,179,444 | - | - | - |
| Current Debt | $5,179,444 | - | - | - |
| Other Current Borrowings | $5,179,444 | - | - | - |
| Net Debt | - | $347,572 | - | - |
| Long Term Debt And Capital Lease Obligation | - | $4,924,612 | - | - |
| Long Term Debt | - | $4,924,612 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $28,466,501 | $25,306,695 | $22,607,730 | $21,872,905 |
| Total Non Current Liabilities Net Minority Interest | $15,435,053 | $18,347,019 | $11,205,145 | $9,189,739 |
| Tradeand Other Payables Non Current | $0 | $0 | $0 | $0 |
| Current Liabilities | $13,031,448 | $6,959,676 | $11,402,585 | $12,683,166 |
| Other Current Liabilities | $2,847,543 | $2,357,903 | $2,453,251 | $2,621,611 |
| Payables And Accrued Expenses | $5,004,461 | $4,601,773 | $8,949,334 | $10,061,555 |
| Payables | $3,425,314 | $2,728,212 | $3,911,973 | $5,823,000 |
| Accounts Payable | $3,425,314 | $2,728,212 | $3,911,973 | $5,823,000 |
| Other Non Current Liabilities | - | - | $48,072 | $108,500 |
| Total Tax Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $-14,227,659 | $-19,585,882 | $-18,055,449 | $-401,303 |
| Total Equity Gross Minority Interest | $-14,227,659 | $-19,585,882 | $-18,055,449 | $-401,303 |
| Stockholders Equity | $-14,227,659 | $-19,585,882 | $-18,055,449 | $-401,303 |
| Gains Losses Not Affecting Retained Earnings | $-718,916 | $-631,576 | $-430,947 | $-292,468 |
| Other Equity Adjustments | $-718,916 | $-631,576 | $-430,947 | $-292,468 |
| Retained Earnings | $-156,675,995 | $-144,181,735 | $-133,396,933 | $-110,939,074 |
| Other | ||||
| Ordinary Shares Number | $4,706,246 | $3,963,045 | $3,459,911 | $3,385,642 |
| Share Issued | $4,706,246 | $3,963,045 | $3,459,911 | $3,385,642 |
| Tangible Book Value | $-14,227,659 | $-19,585,882 | $-18,055,449 | $-401,303 |
| Invested Capital | $-9,048,215 | $-14,661,270 | $-18,055,449 | $-401,303 |
| Working Capital | $816,525 | $-1,971,792 | $-7,804,281 | $7,721,526 |
| Total Capitalization | $-14,227,659 | $-14,661,270 | $-18,055,449 | $-401,303 |
| Additional Paid In Capital | $143,167,204 | $125,227,389 | $115,772,396 | $110,829,900 |
| Capital Stock | $48 | $40 | $35 | $339 |
| Common Stock | $48 | $40 | $35 | $339 |
| Dueto Related Parties Non Current | $15,435,053 | $13,422,407 | $11,157,073 | $9,081,239 |
| Current Accrued Expenses | $1,579,147 | $1,873,561 | $5,037,361 | $4,238,555 |
| Net PPE | $390,869 | $732,929 | $953,977 | $1,066,910 |
| Accumulated Depreciation | $-612,245 | $-524,639 | $-495,638 | $-283,682 |
| Gross PPE | $1,003,114 | $1,257,568 | $1,449,615 | $1,350,592 |
| Other Properties | $1,003,114 | $1,257,568 | $1,449,615 | $1,350,592 |
| Dueto Related Parties Current | - | - | - | $0 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-5,925,168 | $-9,555,476 | $-15,836,073 | $-19,116,889 |
| Operating Activities | ||||
| Operating Cash Flow | $-5,925,168 | $-9,555,476 | $-15,762,512 | $-18,866,843 |
| Cash Flow From Continuing Operating Activities | $-5,925,168 | $-9,555,476 | $-15,762,512 | $-18,866,843 |
| Operating Gains Losses | $169,800 | $-1,973,555 | $-266,780 | $-2,790,809 |
| Investing Activities | ||||
| Investing Cash Flow | - | $0 | $-73,561 | $-250,046 |
| Cash Flow From Continuing Investing Activities | - | $0 | $-73,561 | $-250,046 |
| Capital Expenditure | - | - | $-73,561 | $-250,046 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $14,454,941 | $5,800,000 | $0 | $0 |
| Financing Cash Flow | $14,721,897 | $10,819,986 | $-407,173 | $-155,599 |
| Cash Flow From Continuing Financing Activities | $14,721,897 | $10,819,986 | $-407,173 | $-155,599 |
| Net Other Financing Charges | $-173,353 | - | - | - |
| Net Common Stock Issuance | $14,454,941 | $5,800,000 | $-477,639 | $-157,194 |
| Common Stock Issuance | $14,454,941 | $5,800,000 | $0 | $0 |
| Repurchase Of Capital Stock | - | $0 | $-477,639 | $-157,194 |
| Other | ||||
| Issuance Of Debt | $0 | $5,000,000 | $0 | $0 |
| Interest Paid Supplemental Data | $9,516 | $13,135 | $27,509 | $10,820 |
| End Cash Position | $13,360,340 | $4,577,040 | $3,367,229 | $19,635,725 |
| Beginning Cash Position | $4,577,040 | $3,367,229 | $19,635,725 | $38,888,828 |
| Effect Of Exchange Rate Changes | $-13,429 | $-54,699 | $-25,250 | $19,385 |
| Changes In Cash | $8,796,729 | $1,264,510 | $-16,243,246 | $-19,272,488 |
| Proceeds From Stock Option Exercised | $440,309 | $19,986 | $70,466 | $1,595 |
| Net Issuance Payments Of Debt | $0 | $5,000,000 | $0 | $0 |
| Net Long Term Debt Issuance | $0 | $5,000,000 | $0 | $0 |
| Long Term Debt Issuance | $0 | $5,000,000 | $0 | $0 |
| Change In Working Capital | $3,288,718 | $459,728 | $2,897,144 | $8,766,583 |
| Change In Other Working Capital | $1,908,600 | $2,230,086 | $2,543,988 | $2,977,838 |
| Change In Payables And Accrued Expense | $1,409,906 | $-1,576,185 | $107,567 | $6,085,690 |
| Change In Accrued Expense | $720,196 | $-393,771 | $2,025,124 | $3,424,921 |
| Change In Payable | $689,710 | $-1,182,414 | $-1,917,557 | $2,660,769 |
| Change In Account Payable | $689,710 | $-1,182,414 | $-1,917,557 | $2,660,769 |
| Change In Prepaid Assets | $-29,788 | $-194,173 | $245,589 | $-296,945 |
| Other Non Cash Items | $254,832 | $717,490 | - | $-2,790,809 |
| Stock Based Compensation | $2,673,997 | $1,810,226 | $3,860,366 | $3,026,846 |
| Depreciation Amortization Depletion | $181,745 | $215,437 | $204,617 | $121,749 |
| Depreciation And Amortization | $181,745 | $215,437 | $204,617 | $121,749 |
| Depreciation | $181,745 | $215,437 | $204,617 | $121,749 |
| Gain Loss On Sale Of Business | $0 | $-185,351 | $0 | - |
| Net Income From Continuing Operations | $-12,494,260 | $-10,784,802 | $-22,457,859 | $-27,991,212 |
| Common Stock Payments | - | $0 | $-477,639 | $-157,194 |
| Net PPE Purchase And Sale | - | $0 | $-73,561 | $-250,046 |
| Purchase Of PPE | - | $0 | $-73,561 | $-250,046 |
| Net Short Term Debt Issuance | - | - | - | - |
| Short Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-22